AstraZeneca announced a $50 billion investment plan to expand its U.S. manufacturing and research infrastructure through 2030, including the largest facility it has ever built in Virginia focused on producing small molecules and oligonucleotides. This commitment is part of AstraZeneca's strategy to increase its U.S. revenue share to 50% by 2030 and supports its ambition to launch 20 new medicines by decade-end. The expanded operations will bolster AstraZeneca’s drug supply resilience and innovation capacity amidst rising concerns over pharmaceutical tariffs and supply chain security.